Quick Answer
Denali Therapeutics Inc. reported Stockholders Equity of $1.01 billion for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -17.6% in Stockholders Equity from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $539.03 million | Q2 2018: $490.27 million | Q3 2018: $461.18 million | Q1 2019: $516.65 million | Q2 2019: $475.17 million | Q3 2019: $438.20 million | Q1 2020: $545.31 million | Q2 2020: $502.17 million | Q3 2020: $882.55 million | Q1 2021: $1.11 billion | Q2 2021: $1.07 billion | Q3 2021: $1.01 billion | Q1 2022: $917.93 million | Q2 2022: $884.45 million | Q3 2022: $811.30 million | Q1 2023: $966.71 million | Q2 2023: $1.19 billion | Q3 2023: $1.12 billion | Q1 2024: $1.46 billion | Q2 2024: $1.39 billion | Q3 2024: $1.32 billion | Q1 2025: $1.12 billion | Q2 2025: $1.03 billion | Q3 2025: $926.20 million.
- Over the full 11 years of available data (2015 to 2025), Denali Therapeutics Inc.'s Stockholders Equity has grown by 6,584.3%.
- Historical annual values: Fiscal year 2025: $1.01 billion | Fiscal year 2024: $1.23 billion | Fiscal year 2023: $1.03 billion | Fiscal year 2022: $1.04 billion | Fiscal year 2021: $962.29 million | Fiscal year 2020: $1.15 billion | Fiscal year 2019: $394.89 million | Fiscal year 2018: $546.85 million | Fiscal year 2017: $465.80 million | Fiscal year 2016: -$94.15 million | Fiscal year 2015: -$15.63 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: